New recommendations for Hepatitis C management
New Australian recommendations for the management of hepatitis C virus (HCV) infection have been released in a consensus statement, with a summary published online this week by the Medical Journal of Australia.
Author of the MJA summary, Professor Alexander Thompson, wrote that the timing was right for the new recommendations in the wake of the listing of several direct-acting antiviral (DAA) therapies for HCV by the Pharmaceutical Benefits Scheme earlier this month.
“The introduction of DAA therapies for HCV that are highly effective and well tolerated is a major medical advance,” Professor Thompson wrote. ‘All Australians living with HCV should now be considered for antiviral therapy.”
Read the MJA article and summary of the Australian recommendations for the management of hepatitis C virus infection: a consensus statement 2016.
